TICKERNERD
Menu
PAHCPAHCHealthcare · Drug Manufacturers - Specialty & Generic

PAHC Stock Forecast: Phibro Animal Health Corp. Price Predictions for 2026-2027

Last close, 27 Oct 2026
$38
−1.77% on the day

The 3 Wall Street analysts covering Phibro Animal Health Corp. hold a median 12-month price target of $49 — +27.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.6B
Ticker Nerd rank
90/ 100
Median analyst target
$49
Analysts covering
3
Revenue$396.7M+4.8% y/y
Operating income$48.2M
Net income$21.7M
Free cash flow$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.2%
1M
+11.3%
YTD
+3.5%
1Y
−7.0%
From 52W high
−35.3%
From 52W low
+35.3%
$28
$59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PAHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phibro Animal Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
90/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Quality
94
Volatility
89
Growth
88
Revisions
84
Momentum
54
Issuance
49
Size
39
Accruals
21

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PAHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PAHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60Jan 26Apr 26Jul 26Oct 26PAHCHigh $55Median $49Low $37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
1 Buy2 Hold0 Sell
Low $37Median $49High $55

The green dot is the last close — the median target sits +27.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026CitigroupMaintainsNeutral$62 → $44
14 May 2026CitigroupMaintainsNeutral—
15 Apr 2026CitigroupInitiatesNeutral—
7 Nov 2025JP MorganMaintainsOverweight—
29 Aug 2025B of A SecuritiesMaintainsUnderperform—
7 July 2025JP MorganUpgradeOverweight—
25 June 2025Morgan StanleyMaintainsEqual-Weight—
8 May 2025Morgan StanleyMaintainsEqual-Weight—
10 Feb 2025BarclaysMaintainsUnderweight—
17 Dec 2024Morgan StanleyMaintainsEqual-Weight—
12 Nov 2024BarclaysMaintainsUnderweight—
10 Sept 2024JP MorganInitiatesNeutral—
30 Aug 2024B of A SecuritiesMaintainsUnderperform—
10 May 2024BarclaysMaintainsUnderweight—
9 Nov 2023Morgan StanleyMaintainsEqual-Weight—
1 Sept 2023Roth MKMReiteratesBuy—
31 Aug 2023Morgan StanleyMaintainsEqual-Weight—
29 Aug 2023Roth MKMReiteratesBuy—
27 July 2023Morgan StanleyReiteratesEqual-Weight—
4 May 2023Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PAHC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

PAHC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 27 Oct 2026, Phibro Animal Health Corp. returned −7.0% against +13.5% for the S&P 500, dividends included.

PAHC vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140Jan 26Apr 26Jul 26Oct 26PAHCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PAHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.6%
Analysts raising
5
Analysts cutting
0
Fundamentals

Phibro Animal Health Corp. (PAHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.8×

Cheaper than 44% of US stocks

Price / sales
1.0×

Cheaper than 67% of US stocks

Price / book
4.0×

Cheaper than 23% of US stocks

EV / EBITDA
9.3×

Cheaper than 40% of US stocks

Growth & margins
Revenue growth (YoY)
4.8%

Higher than 39% of US stocks

Earnings growth (YoY)
26.0%

Higher than 64% of US stocks

Gross margin
33.9%

Higher than 40% of US stocks

Operating margin
10.6%

Higher than 65% of US stocks

Net margin
6.6%

Higher than 63% of US stocks

Returns & dividend
Return on equity
29.7%

Higher than 87% of US stocks

Return on assets
8.5%

Higher than 89% of US stocks

Dividend yield
1.3%

Higher than 73% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Phibro Animal Health Corp. (PAHC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Phibro Animal Health Corp. has a market value of $1.6B and an enterprise value of $2.3B.

  • Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 4.8% year on year.

  • Net income over the same four quarters: $99.7M, a 6.6% net margin.

  • Diluted earnings per share, trailing twelve months: $2.44.

  • Free cash flow in the twelve months to 30 June 2026: $9.9M, after $59.1M of capital spending.

  • Phibro Animal Health Corp. spent $19.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 40.6M.

  • Trailing P/E: 15.8×; forward P/E: 10.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.25%, paying out 20% of earnings.

  • Phibro Animal Health Corp. employs 2,605 people — $583K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

PAHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PAHCPhibro Animal Health Corp.$1.6B90
ANIPANI Pharmaceuticals, Inc.$1.6B95
PCRXPacira Biosciences, Inc.$1.5B100
ETONEton Pharmaceuticals, Inc.$1.5B99
ALVOAlvotech$1.9B32
XERSXeris Biopharma Holdings, Inc.$1.9B85
BCRXBioCryst Pharmaceuticals, Inc.$2.0B88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Phibro Animal Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PAHC news & analysis

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

Zacks Investment Research · 27 Oct 2026neutral

Zacks Investment Research describes its focus on its Rank system, which uses earnings estimates and estimate revisions, while also monitoring value, growth, and momentum trends. The excerpt raises whether PAHC is of interest to value investors but provides no company-specific assessment.

Why it matters — PAHC watchers may note the article's screening framework, though the excerpt does not state a conclusion about PAHC.

Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?

Zacks Investment Research · 23 Oct 2026positive

Zacks Investment Research says Phibro has a strong history of earnings surprises and currently has two key factors it considers supportive of a likely beat in its next quarterly report.

Why it matters — PAHC watchers may consider the article’s assessment of the company’s earnings history and setup ahead of its next report.

PAHC or SYK: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 21 Oct 2026neutral

Zacks Investment Research compared Phibro Animal Health and Stryker as possible value stocks in the Medical - Products sector, asking which presents the better value opportunity.

Why it matters — The item frames PAHC in a value-stock comparison with Stryker, which may interest investors tracking PAHC's valuation.

Is it the Right Time to Add Phibro Stock to Your Portfolio?

Zacks Investment Research · 8 Oct 2026neutral

The article notes that Phibro Animal Health’s Animal Health segment is benefiting from growth in MFA, vaccines and mineral nutrition. It also identifies tariffs, costs and currency swings as risks to the company’s outlook.

Why it matters — PAHC watchers may weigh the cited growth drivers against the operational and currency risks highlighted in the article.

PAHC vs. HAE: Which Stock Is the Better Value Option?

Zacks Investment Research · 5 Oct 2026neutral

A Zacks Investment Research article compares Phibro Animal Health (PAHC) with Haemonetics (HAE) as potential value options within the Medical - Products sector, raising the question of which presents the better value opportunity. The piece evaluates both stocks from a value-investing perspective.

Why it matters — A PAHC watcher would care because the comparison offers a value-focused evaluation of the company relative to a sector peer, providing context on how analysts perceive its investment appeal.

FAQ

Frequently asked questions about PAHC stock

What is the PAHC stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Phibro Animal Health Corp. have a median 12-month price target of $49, with estimates ranging from $37 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PAHC stock a buy right now?

Of the 3 analysts covering Phibro Animal Health Corp., 1 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phibro Animal Health Corp. 90 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PAHC?

As at 27 Oct 2026, Phibro Animal Health Corp. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will PAHC stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +27.8% from the last close, and Ticker Nerd's factor model ranks Phibro Animal Health Corp. 90 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PAHC stock forecast for 2030?

No analyst covering Phibro Animal Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PAHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $55 over the next 12 months.

How has PAHC stock performed over the past year?

Phibro Animal Health Corp. returned -7.0% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phibro Animal Health Corp. do?

Phibro Animal Health Corporation Class A Common Stock represents ownership in Phibro Animal Health Corporation, a global animal health and mineral nutrition company. Phibro develops, manufactures, and markets products for food-producing and companion animals, supporting sectors such as poultry, swine, beef and dairy cattle, aquaculture, and pets.

What is the latest news on PAHC?

The most recent item we track (Zacks Investment Research, 27 Oct 2026): "Should Value Investors Buy Phibro Animal Health (PAHC) Stock?". Zacks Investment Research describes its focus on its Rank system, which uses earnings estimates and estimate revisions, while also monitoring value, growth, and momentum trends. The excerpt raises whether PAHC is of interest to value investors but provides no company-specific assessment.

Company

About Phibro Animal Health Corp.

Phibro Animal Health Corporation Class A Common Stock represents ownership in Phibro Animal Health Corporation, a global animal health and mineral nutrition company. Phibro develops, manufactures, and markets products for food-producing and companion animals, supporting sectors such as poultry, swine, beef and dairy cattle, aquaculture, and pets. Its portfolio spans animal health solutions, mineral nutrition products, and performance products used in livestock production and animal care. The company serves customers across the agricultural and veterinary supply chains, where its offerings help address nutrition, health, and productivity needs in animal operations. Phibro Animal Health Corporation is headquartered in Teaneck, New Jersey, and its Class A common stock is one of the company’s primary publicly traded equity classes.

CEO Mr. Daniel M. Bendheim J.D. · 2,605 employees · United States · https://www.pahc.com